A new treatment for ovarian cancer may improve response rates -
Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet oncology a new treatment for ovarian cancer can improve the response rate (increase the rate of tumor shrinkage) and prolong the time until as cancer recurrence. In addition, this breakthrough has shown a tendency to improved survival, although these data are not yet mature
Trebananib (officially called AMG 386, Amgen). Is a first in its category peptide-Fc fusion protein (or peptibody) that target angiogenesis (growth of new blood vessels in cancerous tumors) by inhibiting the binding of both angiopoietin-1 and 2 for the Tie2 receptor. This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor (VEGF) such as bevacizumab (Avastin, Genentech).
Trebananib does not increase the risk of hypertension (high blood pressure) and bowel perforation as bevaciuzmab, but has a similar impact on the removal of the tumor and delay the progression of cancer.
Neither agent showed an increase of the final survival at this stage. Trinova-1 (Trebananib In Ovarian Cancer - 1; ClinicalTrials.gov, NCT004749) was a prospective randomized Phase III clinical trial that added trebananib or placebo to standard chemotherapy (weekly paclitaxel) in 919 patients relapsing women with cancer ovarian from 179 sites in 32 countries.
The trial was led by Professor Bradley J. Monk MD who heads the Division of Gynecologic Oncology at the University of Arizona Cancer Center at St. Joseph of Phoenix and sponsored by Amgen. Dr. Monk of the site was also the largest enrollment site in Arizona.
"This is an exciting new targeted drug in the treatment of recurrent ovarian cancer. Recurrent ovarian cancer is almost always fatal, and new treatments are desperately needed," said Dr. Monk . "Trinova-1 also showed that angiogenesis is a complex process in oncology and many new targets as angiopoietin 1/2 will allow us to more effectively inhibit the growth of new blood vessels needed for the growth of cancer, metastasis and progression. If we can stop cancers from developing by choking their blood supply, we can help our patients feel better and live longer. "
Amgen, the manufacturer trebananib has not yet filed the agent with the Food and Drug Administration (FDA) but also recorded two other Phase III trials for ovarian cancer not yet had reported results (Trinova-2 [NCT01281254] and Trinova-3 [NCT01493505]).
Trinova-2 assesses pegylated liposomal doxorubicin in combination with placebo or trebananib for previously treated patients with cancer ovarian while Trinova-3, also known as ENGOT -Ov2 and Gynecologic Oncology Group -. 3001, studying the use of trebananib in the treatment of first line added to carboplatin / paclitaxel the results of these additional tests are expected in a year and we hope to add a successful application to FDA approval making the agent available to American women with ovarian cancer.
the study will first reported in editions online Lancet Oncology and in paper editions.
EmoticonEmoticon